**Plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD).**

Mona M. Redaa,Hala G. Alnadyb, Menan A. Rabiec, Eman A. AwadAllad, Shaimaa A. Zakie.

1. Professor of psychiatry, Medical studies department, Institute of postgraduate childhood studies, Ain-shams university
2. Research professor of child health, Child health department, Medical research division, National research center
3. Assistant professor of psychiatry, Faculty of medicine, Ain- shams university
4. Researcher clinical pathology, Medical research division, National research center
5. Assistant researcher child health department, medical research division, National research center
6. Abstract:

**Background:**ADHD is a common childhood disorder with serious effect on the patient and his Family’s life. Recent evidence suggests a relation between ADHD and BDNF a neurotrophin responsible forneuronalplasticity and act as a neurotransmitter modulator.**The Aim of the study:** To know the possible relation between BDNF level and ADHD so it could be used as a potential marker for this disorder.**Subjects and methods:**fifty three cases ofADHD were selected 29 patients were drug naïve and 24 patients were Receiving pharmacological treatment. The ADHD cases underwent IQ test (WISC), Conner's test to assess severity ofdifferent symptoms, 3 ml blood sample before noon were collectedto measure plasma level of BDNF. After full assessment patients were categorized into 3diagnostic categories (hyperactive impulsive type, inattentive type, and combined type). Control group consisted of thirty normal volunteer children, with no psychiatric or neurological disorder. 3mlnon clotted blood samples were collected from them before noon. **Results**: In our study the mean plasma BDNF levels weresignificantly higher in ADHD patients than in normal controls (p value was 0.010).Conclusion:Our study suggests that there is an increase of plasma BDNF levels in ADHD patients.

**Introduction:**

Attention-deficit hyperactivity disorder (ADHD) has been identified as an important psychiatric condition in terms of its prevalence (around 5% worldwide) and its impact on quality of life for patients and their families **(Cho et al., 2010).** Also ADHD is the most commonly diagnosed behavioral disorder of childhood **(American Academy of Pediatrics, 2000).**

Attention-deficit/hyperactivity disorder (ADHD) is characterized by hyperactivity, diminished sustained attention and higher levels of impulsivity in a child or adolescent than expected for someone of that age and developmental level **(Sadock and Sadock, 2007).** These core behavioral symptoms must be pervasive across situations, persistent for more than 6 months and observed before the age of 7 years, as defined by the diagnostic and statistical manual of mental disorders (DSM-IV-TR) issued by **(American Psychiatric Association, 2000).**

These behavioral manifestations contribute to diminish academic, occupational and social functioning, and have neurobiological bases. **(De La Fuente A, 2013).** 30 to 50% of those individuals diagnosed in childhood continue to have symptoms into adulthood. As they mature**(Bálint et al, 2008).**

The etiology of ADHD is now viewed to be pathophysiological and clinically heterogeneousentity, hypotheses on the etiology of ADHD have evolved from simpleone-cause theories to multi-factorial processes that reflect the confluenceof many types of risk factors, including genetic, neurochemical,environmental and psychosocial factors **(Biederman and Faraone, 2005).**

Genetic research on ADHD started with the finding that hyperactivity tends to aggregate in families since then, family studies have shown that ADHD shows familial clustering both within and across generations. Increased rates of ADHD among the parents and siblings of ADHD children have been observed**(Franke et al.,2012).**

Evidence fromvarious sources suggests primaryinvolvement of the dopaminergic system.Molecular genetic studies alsoindicate a linkage of genetic polymorphisms in the dopaminergicsystem, such as dopamine D4 and D5 receptors, and dopaminetransporter (DAT), to ADHD **(Bobb et al., 2005).**

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that modulates different aspects of neuronal function during development and in the mature nervous system **(Gottmann et al., 2009).** Recent reports have suggested apathophysiological role of BDNF in ADHD **(Shim et al., 2008).**

It acts through tropomyosin-related kinase B (TrkB) receptors either pre- and postsynaptically to modulate long-term potentiation (LTP), which serves as a molecular model for the synaptic events underlying memory formation **(Farmer et al., 2004).** Furthermore, BDNF enhances glutamatergic synaptic transmission **(Gottmann et al., 2009)** and has been strongly implicated in spatial learning **(Yamada et al., 2002)**

First, earlier studiesdemonstrated that BDNF plays a key role inthe survival and differentiation of midbraindopaminergic neurons invivo **(Hyman et al., 1991)** and in vitro **(Spina et al., 1992).**

Since dysfunction in the midbrain system iscrucial in ADHD pathogenesis**(Solanto, 2002),** adecreased midbrain BDNF activity maycause midbrain dopaminergic dysfunction,and therefore, resulting in ADHD. Second, psychostimulants such as methylphenidateare the agents commonly used in thetreatment of ADHD. The classical actionmechanism of psychostimulants involvesenhancement of the release of dopamineand norepinephrine in the midbrain. BDNFhas been shown tomodulate the release ofdopamine through activation of TrkB(tropomyosin-related kinase B) receptors **(Blochl and Sirrenberg, 1996)**and has also been implicated in the releaseof dopamine as well as in dopamine-relatedbehaviors induced by psychostimulant, methamphetamine **(Narita et al., 2003)**.

**Subjects and Methods:**

The present study included 83 subjects; thirty healthy subject of both sexes representing the control group, 29 new ADHD cases who have received no medical treatment (drug naïve) of both sexes and 24 ADHD cases who have taken pharmacological treatment for ADHD of both sexes.

The patients were recruited from the regular attendants of the psychiatric Clinic in the institute of post graduate childhood studies and Institute of Psychiatry, Ain Shams University hospitals.The Controls were recruited from the child health clinic of the National research center.

Cases were included according to; Age from 6 to 15years and Casesbeing diagnosed with ADHD according to the diagnostic Criteria for Attention-Deficit/Hyperactivity Disorder of the Diagnostic and statistical manual of psychiatric disease; Cases with Full scale IQ lower than 70,Bipolar affective disorders, Neurological and seizure disorders, Pervasive developmental disorders,Chronic tic disorder and Tourette's disorder,Psychotic disorders, were excluded.All patients and controls other than group 2 have not be receiving any medications for at least one month prior to their participation in the study. Written informed consent was obtained from parents after explanation of the aim and procedures of the study.

All studied children were subjected to;Full medical history and clinical examination. Full psychiatric history and mental status examination using the semi- structured interview to the psychiatric sheet of the institute of post graduate childhood studies. Ain shams university, Auxological Assessment: Growth was assessed through auxological measurements of weight, height and head circumference. Assessment of cognitive function:The Arabic version of the Revised Wechsler Intelligence Scale for Children (WISC-R) (**Wechsler, 1977) (Kamel& Ismaiel, 1993),** The Benton visual retention test; to assess memory **(Benton, 1974) .**The Conners’ parent Rating Scales-Revised (CRS-R) long version was completed by parents to assist in evaluating children for attention deficit/hyperactivity disorder (ADHD)**(Conner’s, 1997)**. Laboratory investigations;For ADHD patients and normal controls, blood sample was drawn from the subjects under complete aseptic conditions between 8 a.m. and noon to exclude the circadian effect of BDNF levels **(Begliuomini et al., 2008).** Approximately 5 ml of plasma was collected on ice in polypropylene tubes using citrate as an anticoagulant. Samples were centrifuged for 15 minutes at 1000 x g at 2-8̊C within 30 minutes of collection, then separated plasma was additionally centrifuged at 10,000 x g for 10 minutes at 2-8̊ C. samples were then stored at - 20̊ C till assay.

The assay employed the quantitative sandwich enzyme immune assay technique. A monoclonal antibody specific for BDNF has been pre-coated onto a micro plate. Standards and samples were pipetted into the wells and any BDNF present was bound by the immobilized antibody. An enzyme linked monoclonal antibody specific for BDNF was added to the wells. Following a wash to remove any unbound antibody – enzyme reagent, a substrate solution was added to the wells and color developed in proportion to the amount of BDNF bound in the initial step. The intensity of the color was measured.

Quantitative determination of plasma BDNF concentrations were detected using human BDNF immunoassay kits. The human BDNF immunoassay kits were manufactured in USA–Catalog No. DBD00 SBD00 PDDBD00, (R and D systems), expiry date at 24 October. 2012. In the National research center labs; kits were stored at 2-8̊ C. plasma dilution (1/20) with sample buffer supplied by the kit is required in order to obtain adequate concentration to measure. Equipment used: ELIZA Reader SLT. SPECTRA and micro titration plate washer.

Statistical Analysis;

Statistical analysis was done on a personal computer using IBM© SPSS© Statistics version 21 (IBM© Corp., Armonk, NY).

Categorical data are presented as number and percentage and between-group differences are compared using the Pearson chi square test or the chi square test for trends for nominal or ordinal data, respectively. Fisher’s exact test is used in place of the chi square test if > 20% of cells in any contingency table had an expected count of < 5.Normality of numerical data distribution was tested using The D’Agostino-Pearson test. Non-normally distributed numerical data are presented as quartiles, minimum, and maximum. Normally distributed data are presented as mean and SD, and intergroup differences are examined using the unpaired Student t test was (for 2 independent groups) or one-way analysis of variance (ANOVA) (for multiple groups).

Correlations among numerical variables are examined using the Pearson moment-product correlation analysis. The Spearman rank correlation is used for ordinal variables. All P values are two-sided. P < 0.05 is considered statistically significant.

**Results;**

**Table (1):comparison between patients and healthy controls as regard age,Weight (kg), Weight for age (percentile), Height (cm), Height for age (percentile), BMI (kg/m2), BMI for age (percentile), Head circumference (cm).**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| General characteristics | Patients (mean) | Controls (mean) | Patients (SD) | Controls (SD) | P value |
| age | 9.0 | 9.2 | 2.6 | 2.3 | 0.779 |
| Weight (kg), | 31.9 | 31.8 | 10.5 | 11.1 | 0.959 |
| Weight for age (percentile), | 59.5 | 58.1 | 26.3 | 26.7 | 0.809 |
| Height (cm), | 130.9 | 132.9 | 13.8 | 11.6 | 0.482 |
| Height for age (percentile), | 45.0 | 49.0 | 26.0 | 26.4 | 0.515 |
| BMI (kg/m2), | 18.0 | 17.5 | 2.7 | 3.0 | 0.479 |
| BMI for age (percentile) | 71.6 | 63.7 | 17.8 | 26.1 | 0.148 |
| Head circumference (cm). | 53.4 | 52.6 | 2.8 | 1.9 | 0.128 |

**Table (1);** shows non-significant difference between ADHD patients and controls as regard age, Weight (kg), Weight for age (percentile), Weight for age (Z–score), Height (cm), Height for age (percentile), Height for age (Z–score), BMI (kg/m2), BMI for age (percentile), BMI for age (Z–score), Head circumference (cm). P < 0.05 is significant. P> 0.05 is non-significant. BMI= body mass index. SD= standard deviation.

**Table (2): Comparison between patients and healthy controls as regards;Gender, Consanguinity and Handedness.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **General characteristics** | **Gender** | | | | **p- value** | **Consanguinity** | | | | **p- value** | **Handedness** | | | | **p-**  **value** |
|  | **Male** | | **Female** | |  | **No consanguinity** | | **consanguinity** | |  | **Right** | | **Left** | |  |
|  | **No** | **%** | **No** | **%** |  | **No** | **%** | **No** | **%** |  | **No** | **%** | **No** | **%** |  |
| **cases** | **41** | **77.4** | **12** | **22.6** | **0.011** | **33** | **62.3** | **20** | **37.7** | **0.094** | **47** | **88.7** | **6** | **11.3** | **1.0** |
| **controls** | **15** | **50.0** | **15** | **50.0** | **24** | **80** | **6** | **20** | **27** | **90** | **3** | **10** |

**Table (2):** shows significant difference between cases and controls as regard sex ; out of 53 patients 41 were males (77.4%) while in the control group 15 were males (50%) . as regard consanguinity and handedness no statistical difference was found between cases and controls.P < 0.05 is significant. P> 0.05 is non-significant.

**Table (3):Comparison between patients and controls as regard perinatal conditions and infancy.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  | Controls | Cases | p-value |
| **Pregnancy** | *Uneventful* | N | 24 | 42 | 0.082 |
|  |  | % | 80.0% | 79.2% |
|  | *GDM* | N | 1 | 5 |
|  |  | % | 3.3% | 9.4% |
|  | *PE* | N | 5 | 2 |
|  |  | % | 16.7% | 3.8% |
|  | *Bad emotional status* | N | 0 | 4 |
|  |  | % | 0.0% | 7.5% |
| **Delivery** | *SVD* | N | 17 | 29 | 0.864 |
|  |  | % | 56.7% | 54.7% |
|  | *CS* | N | 13 | 24 |
|  |  | % | 43.3% | 45.3% |
| **Postnatal course** | *Normal* | N | 21 | 33 | 0.751 |
|  |  | % | 70.0% | 62.3% |
|  | *Neonatal jaundice* | N | 7 | 17 |
|  |  | % | 23.3% | 32.1% |
|  | *Admission to NICU* | N | 2 | 2 |
|  |  | % | 6.7% | 3.8% |
|  | *Cyanosis* | N | 0 | 1 |
|  |  | % | 0.0% | 1.9% |
| **Infancy** | *Normal* | N | 23 | 39 | 0.921 |
|  |  | % | 76.7% | 73.6% |
|  | *Difficult child* | N | 5 | 11 |
|  |  | % | 16.7% | 20.8% |
|  | *Delayed milestones* | N | 2 | 3 |
|  |  | % | 6.7% | 5.7% |

**Table 3**; shows non-significant difference between cases and controls as regard pregnancy, delivery, postnatal conditions and infancy.P < 0.05 is significant. P> 0.05 is non-significant.


Note GDM= gestational diabetes mellitus, PE= preeclampsia, SVD= spontaneous vaginal delivery, CS= caesarian section, NICU= neonatal intensive care unit.

**Table (4): comparison between cases and Controls in Wechslerintelligence scale and Benton visual retention test.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Controls  No= 30 | | Cases  No=53 | |  |
| **variable** | Mean | SD | Mean | SD | p- value |
| **WISC: Verbal subscales** | 107.3 | 8.8 | 95.5 | 11.2 | <0.001 |
| **WISC: Comprehension** | 11.6 | 2.6 | 9.8 | 2.3 | 0.002 |
| **WISC: Arithmetic** | 10.8 | 1.8 | 8.6 | 2.3 | <0.001 |
| **WISC: Similarities** | 10.5 | 2.2 | 8.8 | 2.9 | 0.004 |
| **WISC: Digit span** | 8.8 | 1.7 | 7.6 | 2.0 | 0.008 |
| **WISC: performance subclasses** | 102.1 | 7.1 | 90.8 | 12.0 | <0.001 |
| **WISC: Picture completion** | 10.0 | 1.5 | 8.4 | 1.7 | <0.001 |
| **WISC: Block design** | 8.7 | 1.3 | 7.8 | 1.8 | 0.018 |
| **WISC: Coding** | 10.3 | 1.9 | 8.4 | 2.5 | <0.001 |
| **WISC: Total IQ** | 104.8 | 7.9 | 92.6 | 11.5 | 0.000 |
| **BVRT: O-E correct score** | 1.2 | 0.9 | 2.0 | 1.5 | 0.003 |
| **BVRT: O-E error score** | 1.9 | 1.3 | 3.0 | 2.3 | 0.008 |


**Table 5;** shows significant statistical difference between ADHD cases and healthy controls as regard Wechsler intelligence subscales and total IQ. Also showing statistically significant difference between cases and controls in Benton visual Retention test scores. P < 0.05 is significant. P> 0.05 is non-significant.

Note WISC= Wechsler intelligence scale for children, IQ= intelligence quotient, BVRT= Benton visual retention test, O-E= difference between observed score and expected score.



**Figure (1): Comparison between Serum BDNF level between Cases and Controls:**

**Figure (1):** showing significant increase in serum BDNF level among cases more than controls. Mean plasmaBDNF level in controls is3138.5, and standard deviation is 2640.7. While mean plasma BDNF in cases is 5476.9 and standard deviation is 5443. p value is 0.010.P < 0.05 is significant. P> 0.05 is non-significant. Note BDNF= Brain derived neurotropic factor, CI= confidence interval.



**Figure (2): prevalence of ADHD subtypes in study population.**

**Figure (2):** showing 22 out of 53 cases were hyperactive impulsive type representing 41.5% of the study population, 18 patients were inattentive representing 34%, 13 patients ere of the combined type representing 34%. Note ADHD= attention deficit hyperactivity disorder. N= number

**Discussion;**

The aim of the present study was to find the relation between plasma BDNF level and ADHD and to investigate the effect of pharmacological therapy on ADHD. In the present study, we investigated the levels of plasmaBDNF in children with ADHD and found that plasma BDNFlevels were significantly higher in children with ADHD than in normalcontrols.Our results came in accordance withthe findings of **Shim** and his colleagues (the first study to investigate the relation between BDNF and ADHD in children);they found that the mean plasma BDNFlevels in ADHD patients were 833.8±371.0pg/ml, whereas 578.5±304.0 pg/ml innormal controls, thus showing significantlyhigher mean plasma BDNF levels in ADHDpatients than in normal controls **(shim et al., 2008).**

However the results of **Sayyah** disagree with our results and found no significant difference between plasma BDNF level in both cases and controls (For control children BDNF plasma level was mean=28689pg/ml, SD+/-12705 and the mean BDNF level 27171 pg/ml , SD+/- 25368.5 **(Sayyah,2009).**

regarding anthropometric measures weight for age height for age and head circumference there were no significant statistical difference between cases and controls this contradicts with **(Holtkamp, 2004 :Pagoto et al., 2009;Waring and Lapane , 2008)**Who found significant relation between obesity and ADHD patients than controls this may be due to the large sample size used in these studies.**Bahrami** stated that children with ADHD face a significant risk of becoming overweight and that there are also significant risks that overweight children may have ADHD**(Bahrami, 2013).** Also**Yang** and colleagues studied A total of 158 Chinese child with ADHD .The prevalence ofobesity, overweight, were 12.0%, 17.1%, respectively, which wereSignificantly higher than in the general Chinese population (2.1%, 4.5%, respectively). Multivariableanalysis showed that the children with the combined subtype of ADHD and the onset of puberty were at a higherrisk of becoming obese or overweight**(Yang et al., 2013)**another reason why our study may contradicts with other studies is the racial difference Yang found the prevalence of overweight and obesity in control children to be 4.5 and 2.1% respectively In Egypt the prevalence of overweight and obesity is 12.1 and 6.2% respectively according to **(Salazar-Martinez et al., 2006).**

In our study out of 53 patients 41 were males (77.4%), 12 were females representing (22.6%) while in the control group 15 were males (50%) and 15 were females (50%). This comes in accordance with **Jamison** who stated that ADHD is much more common among males than females; boys are two to three times more likely to have ADHD than girls. They are up to nine times more likely than girls to be referred for evaluation and treatment. The difference in referral rates between ADHD boys and girls is likely due to ADHD boys having more behavior problems than ADHD girls**(Jamison, 2000).**

As for consanguinity our results showed non-significant statistical difference between cases and controls regarding parental consanguinity this contradict with and**Al-Sharbati** andcolleagues who found that The contribution of consanguinity and a history of acquired brain injury to be common features **(Al-Sharbati et al.,2011).**

Handedness was studied and we found that there were no significant difference between patients an controls regarding handedness, this was consistent with Ahmad **Ghanizadeh** who stated that Left- or right-hand preference was not associated with age, gender, inattentiveness score, hyperactivity-impulsivity score, comorbid psychiatric problems, developmental coordination problems score, or parental characteristics**(Ghanizadeh, 2013).**

In our study we also studied the effect of perinatal factors in the etiology of ADHD and we found non-significant statistical difference between cases and controls with this regards. This contradicts with **Ketzer** et al, who found that using Conditional logistic regression analysis children and adolescents whose mothers presented more Prenatal, delivery and early post-natal problems had a significantly higher risk for ADHD **(Ketzer et al., 2012),**the study of Ketzer and colleagues Perinatal complications were assessed by direct interview with biological mothers and supplemented with medical records when possible.**Amor et al**. found greater number of neonatal complications in their sample of 50 ADHD children compared with their 50 unaffected siblings.No differences between cases and controls related to low birth and to maternal alcohol and tobacco consumption during pregnancy were found**(Amor et al, 2005).** In another study, disruptive behavior disorders were significantly associated with maternal physical problems during pregnancy and delivery, especially acute anoxia/hypoxia **(Allen et al.,1998).**The difference between our results and these previous studies may be because they applied several different scales and also due to the fact that maternal smoking; a very important prenatal risk factor was not found in our study.

We studied the effect of ADHD on IQ; total scores and subscales, by comparing cases and controls ADHD cases had lower scores in all scores total, performance subscale and verbal subscale;the mean of the Verbal subscales in controls was 107.3+/- 8.8 while in Cases it was 95.5 +/- 11.2. The performance subscales; mean value in controls is 102. +/- 17.1 while cases mean value was 90.8+/- 12.0 .this come in accordance with **Fraiser** and colleagues who stated thatEffect sizes for overall intellectual ability (Full Scale IQ) were significantly different between ADHD and healthy participants. Effect sizes for Full Scale IQ were significantly smaller than those for spelling and arithmetic achievement tests and marginally significantly smaller than those for continuous performance tests but were comparable to effect sizes for all other measures. These findings indicate that overall cognitive ability is significantly lower among persons with ADHD and that Full Scale IQ may show as large a difference between ADHD and control participants as most other measures **(Frazier et al.,2004).Voigt** also stated that similar to the general population, children with ADHD may have a broad range of cognitive abilities and reported that ADHD is more likely to be present in the context of developmental delay, at the level of borderline-to-mild intellectual disability **(Voigt et al., 2006).** On the other handKaplan applied full scale Wechsler intelligence scale on 63 children with ADHD, 69 children with reading difficulties (RD), and 68 children with comorbid ADHD + RD, the distributions of estimated Full Scale IQs for each of the three groups of children did not differ significantly from a normal distribution, with the majority of children (more than 50%) in each group scoring in the average range. The percentage of children with ADHD who scored in the above-average range was not significantly higher than the percentages of children in the other two groups. It was concluded that children with ADHD are no more likely to have an above-average IQ than are other children **(Kaplan et al., 2000)**

In the present study we found that children with ADHD had significant memory impairment compared with healthy controls, we applied the Benton visual retention test toassess visual perception and visual memorymeasures visuo-spatial abilities andimmediate spatial memory abilities. and we found mean difference between observed and expected true score in controls 1.2+/- 0.9 while in controls the difference was 2.0 +/- 1.5, this comes in accordance with Marzocchi et al. who compared ADHD patients together with normal controls and reading disabled children and found significant immediate memory imparment in ADHD children compared to controls**(Marzocchi et al., 2008).**

The prevalence of ADHD subtypes in the present study population was 22 out of 53 cases were hyperactive impulsive type representing 41.5% of the study population, 18 patients were inattentive representing 34%, 13 patients were of the combined type representing 34%. A meta-analysis by **Willcutt** stated that reviewing several studies that discussed the prevalence of ADHD subtype When subtypes were defined based only on symptom criteria, ADHD (inattentive type) was the most common subtype based on parent ratings alone, teacher ratings alone, self-report ratings, and parent-teacher agreement (38–57 % of all individuals with ADHD). The relative frequencies of ADHD( combined subtype) and ADHD (Hyperactive subtype) varied by reporter; more individuals with ADHD met the criteria for ADHD (Hyperactive subtype) than ADHD (Combined subtype) based on parent ratings (37 % vs. 25 %) and self-report ratings (36 % vs. 22 %), whereas a higher proportion met the criteria for ADHD (Combined subtype) than ADHD (hyperactive subtype) when ADHD was defined by teacher ratings or was in agreement between parents and teachers (24–30 % vs. 19–20 %) **(Willcutt,2012)** When applying the full DSMIV criteria; ADHD ( inattentive subtype) remained the most common subtype when parent, teacher, or self-report ratings were used to define ADHD based on full DSM-IV criteria, but the rate of ADHD (Combined subtype) was higher than the rate of ADHD (Inattentive) for best estimate diagnoses. The estimated prevalence of ADHD (Hyperactive) was lower than ADHD (Combined) or ADHD (Inattentive) for all algorithms that applied to the full diagnostic criteria (i.e., 13–17 % of all individuals with ADHD), reflecting the lower rates of functional impairment in groups that met symptom criteria for ADHD (Hyperactive) versus ADHD (Combined) or ADHD(inattentive)**(Willcutt et al., 2012).**

**Conclusion**;

Plasma BDNF level is higher in patients with ADHD than in normal control further increase in BDNF level occurs with pharmacological treatment

**Limitation of the study;**

Different ranges of plasma BDNF of levelshave previously been reported in healthysubjects, and these differences are mostlikely due to different assay methods used,such as the R&D ELISA kit or the PromegaBDNF kit. DifferentELISA methods or different types ofsampling tubes might lead to differences inmeasured BDNF levels.

**Recommendations;**

Further studies are required to determine thesource and role of circulating BDNF inADHD. Future studies are needed toestablish the most reliable, accurate methodfor measurement of BDNF and to determinewhich source of BDNF platelets, plasma,serum, or whole blood provides the mostreliable biological marker of ADHD. Larger sample size should be used to identify whether BDNF level can be used as a marker for ADHD.

**References;**

1. **Allen NB, Lewinsohn PM, Seeley JR.,(1998):** Prenatal and perinatal influences on risk for psychopathology in childhood and adolescence. Dev Psychopathology;10:513-29.
2. **Al-Sharbati MM, ZaidanZAJ, Dorvlo ASS, Al-Adawi S., (2011):** Characteristics of ADHD Among Omani Schoolchildren Using DSM-IV: Descriptive Study. Journal of attention disorders; 15: 139-146.
3. **American Academy of Pediatrics, (2000):** Clinical Practice Guideline: Diagnosis and Evaluation of the Child with Attention-Deficit/Hyperactivity Disorder. Pediatrics. 105(5): 1158-1170.
4. **American Psychiatric Association, (2000):** Diagnostic and statistical manual of mental disorders. 4th Edn, (text revised Edn.) Washington: American Psychiatric Publishing.
5. **Amor LB, Grizenko N, Schwartz G, Lageix P, Baron C, Ter-Stepanian M, Zappitelli M, Mbekou V, Joober R., (2005):** Perinatal complications in children with attention-deficit/hyperactivity disorder and their unaffected siblings. Rev Psychiatr Neurosci.; 30(2):120-6.
6. **Bahrami F, (2013):** The importance of the transdiagnostic approach in treating obesity and comorbid psychological disorders such as ADHD. Acta Paediatr. doi: 10.1111/apa.12348. [Epub ahead of print]
7. **Bálint S, Czobor P, Mészáros A, Simon V, Bitter I, (2008):** Neuropsychological impairments in adult attention deficit hyperactivity disorder: a literature review]" (in Hungarian). Psychiatr Hung 23 (5): 324–35.
8. **Begliuomini S, Lenzi E, Ninni F et al.,(2008):** Plasma brain derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm. J Endocrinol;197:429–
9. **Benton A. L, (1974):** the revised visual retention tests 4th ed. New York psychological corporation.
10. **Biederman J and Faraone SV.,(2005):** Attention-deficit hyperactivity disorder. Lancet;366:237–48.
11. **Bobb AJ, Castellanos FX, Addington AM, Rapoport JL., (2005):** Molecular genetic studies of ADHD: 1991–2004. Am J Med Genet B Neuropsychiatr Genet;132:109–25.
12. **Blochl A, and Sirrenberg C.,(1996):** Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors. J Biol Chem;271:21100–7.
13. **Cho SC , Kim HW, Kim BN, Kim JW,Shin MS, Cho DY, Chung S, Jung SW , Yoo HJ , Chung IW , Chung US and Son JW., (2010):** Neurotrophin-3 gene, intelligence, and selective attention deficit in a Korean sample with attention-deficit/hyperactivity disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry; 34: 1065–1069.
14. **Conners, C.K., (1997):** User’s manual and administrative guide of the Conner’s Rating Scales-Revised. Toronto, Ontario, Canada: Multi-Health Systems Inc.
15. **De La Fuente A., Xia S., Branch C., and Li X., (2013):** A review of attention-deficit/hyperactivity disorder from the perspective of brain networks.Front. Hum. Neurosci. 7: 192.
16. **Farmer, J., Zhao, X., van Praag, H., Wodtke, K., Gage, F. H., & Christie, B. R., (2004):** Effects of voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague-Dawley rats in vivo. Neuroscience, 124, 71–79
17. **Frazier TW, Demaree HA, Youngstrom EA.,(2004):** Meta-analysis of intellectual and neuropsychological test performance in attention- deficit/ hyperactivity disorder. Neuropsychology.;18(3):543–55.
18. **Franke B, Faraone S V, Asherson P, Buitelaar J, Bau C H D,Ramos-Quiroga J A, Mick E, Grevet E H, Johansson S,Haavik J, Lesch K-P, Cormand B and Reif A, (2012):** The genetics of attention deficit/hyperactivity disorder in adults, a review. Molecular Psychiatry 17, 960–987.
19. **Ghanizadeh A, (2013):** Lack of Association of Handedness With Inattention and Hyperactivity Symptoms in ADHD.Journal of Attention Disorders; 17 (4): 302-307.
20. **Gottmann, K., Mittmann, T., & Lessmann, V., (2009):** BDNF signaling in the formation, maturation and plasticity of glutamatergic and GABAergic synapses. Experimental Brain Research, 199, 203–234.
21. **Holtkamp, K., Konrad, K., Müller, B., Heussen, N., Herpertz, S., Herpertz-Dahlmann, B.,Hebebrand, J., (2004):**Overweight and obesity in children with Attention-Deficit/Hyperactivity Disorder. Int J Obes Relat Metab Disord. 28 (5), 685–689.
22. **Hyman C, Hofer M, Barde YA et al.(1991):** BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature;350:230–2.
23. **Jamison L.,(2000):** Gender Differences in ADHD Children. Clinical Psychology Associates of North Central Florida; 32605 (352) 336-2888.
24. **Kamel M and Ismaiel E, (1993):** Wechsler Intelligence Scale for Children, Arabic version. El-Nahda El-massryia, Cairo.
25. **Kaplan BJ, Crawford SG, Dewey DM, Fisher GC., (2000):** The IQs of children with ADHD are normally distributed.J Learn Disabil.;33(5):425-32.
26. **Ketzer CR, Gallois C, Martinez AL, Rohde LA, and Schmitz M.,(2012):** Is there an association between perinatal complications and attention-deficit/hyperactivity disorder-inattentive type in children and adolescents?Rev Bras Psiquiatr; 34(3):321-8.
27. **Marzocchi G M, Oosterlaan J, Zuddas A, Cavolina P, Geurts H,Redigolo D, Vio C and Sergeant J A., (2008):**Contrasting deficits on executive functions between ADHD and reading disabled children. Journal of Child Psychology and Psychiatry 49: 5, pp 543–552.
28. **Narita M, Aoki K, Takagi M et al., (2003):** Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience;119:767–75.
29. **Pagoto, S.L., Curtin, C., Lemon, S.C., Bandini, L.G., Schneider, K.L., Bodenlos, J.S., Ma, Y.,(2009):** Association between adult attention deficit/hyperactivity disorder andobesity in the US population. Obesity (Silver Spring). 17 (3), 539–544.
30. **Sadock BJ. AndSadock V A. (2007)**:attention deficit hyperactive disorder in: Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Grebb JA, Pataki CS and Sussman N. (Eds)10th Edition. Lippincott Williams & Wilkins. P1206-1217.
31. **Salazar-Martinez E, Allen B, Fernandez-Ortega C, Torres-Mejia G, Galal O, Lazcano-Ponce E.,(2006):**Overweight and obesity status among adolescents from Mexico and Egypt.Arch Med Res; 37(4):535-42.
32. **Sayyah H., (2009):** BDNF Plasma level in ADHD Children; Correlation to Different Symptomatology. Current psychiatry (Egypt);16 (3):284-94.
33. **Shim S, Hwangbo Y, Kwon Y-J et al., (2008):** Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficithyperactivity disorder (ADHD) in Progress.Neuro-Psychopharmacol Biol Psyciatr;32:1824–28.
34. **Solanto MV.,(2002):** Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res;130:65–71.
35. **Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C., (1992):** Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem. Jul;59(1):99-106.
36. **Voigt RG, Barbaresi WJ, Colligan RC, Weaver AL, Katusic SK.,(2006):** Developmental dissociation, deviance, and delay: Occurrence of attention-deficit-hyperactivity disorder in individuals with and without borderline-to-mild intellectual disability. Dev Med Child Neurol.;48(10):831–5.
37. **Waring, M.E., Lapane, K.L., (2008):** Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. Pediatrics. 122 (1), e1–e6.
38. **Wechsler D, (1977):** Manual for the Wechsler Intelligence Scale for Children –Revised (WISC-R), the Psychological Corporation, NY.
39. **Willcutt EG,(2012):** The Prevalence of DSM-IV Attention Deficit/ Hyperactivity Disorder: A Meta-Analytic Review. Neurotherapeutics; 9(3): 490–499.
40. **Willcutt EG, Nigg JT, Pennington BF, et al.,(2012):** Validity of DSM-IV attention-deficit/hyperactivity disorder dimensions and subtypes. J Abnorm Psychol; doi:10.1037/a0027347.
41. **Yamada, K., Mizuno, M., & Nabeshima, T., (2002):** Role for brain-derived neurotrophic factor in learning and memory. Life Sciences, 70, 735–744.
42. **Yang R, Mao S, Zhang S, Li R, Zhao Z., (2013):** Prevalence of obesity and overweight among Chinese children with attention Deficit Hyperactivity Disorder : a survey in Zhejiang Province, China.BMC Psychiatry. 10;13:133. doi: 10.1186/1471-244X-13-133.

**مستوي العامل التغذوي العصبي ببلازما الدم في الاطفال المصابون بفرط الحركه و نقص الانتباه**

**الملخص :**

**اضطراب فرط الحركه و نقص الأنتباه هو مرض ذو تأثير خطير على المرضى و عائلاتهم. تشير الأدله الحديثه الي العلاقه بين الأضطراب و العامل التغذوي العصبي و هو احد المغذيات العصبيه المسئوله عن المرونه العصبيه كما انه يعمل كمغير للموصلات العصبيه. الهدف من الدراسه: معرفه العلاقه المحتمله بين العامل التغذوي العصبي و اضطراب فرط الحركه حتي نتمكن من معرفه امكانيه استخدامه كمحدد للمرض . خطه البحث: تم اختيار 53 حاله مصابه بفرط الحركه و نقص النتباه 29 منهم لا يتناولون اي علاج دوائي و 24 مريض يتناولون العقاقير الطبيه . تم عمل اختبار وكسلر لقياس ذكاء الأطفال و اختبار كونورز لقياس شده الاعراض المختلفه وتم سحب 3 ملل بلازما من المرضي قبل الظهر. تم تقسيم المرضي بعد التقييم الشامل الي ثلاث مجموعات : مرضي يعانون من فرط الحركه والاندفاع و مرضي يعانون نقص الانتباه و مرضي يعانون من نقص الحركه و فرط الأنتباه معا. تتكون المجموعه الضابطه من 30 طفل طبيعي متطوع . النتائج: تظهر هذه الدراسه ان متوسط العامل التغذوي العصبي في بلازما الدم اعلي في اضطراب فرط الحركه و نقص الانتباه من يتناولون اي ادويه.**